Nanoscience has brought new hope for psoriasis. There have been many treatments available for psoriasis through the years. Now an over the county supplement has brought a solution. Metadichol is an over the counter supplement that is simply policosanol made into a small particle emulsion. Policosanol is the waxy substance found on the sun-splashed parts of plants. The case studies in this new paper that was just published are amazing in how it resolves the issues around this disease that has no apparent resolution in modern medicine.
Metadichol, A Novel ROR Gamma Inverse Agonist and Its Applications in Psoriasis
Raghavan PR* Nanorx Inc Chappaqua, New York, United states
Psoriasis affects 3% of the population worldwide, and there is no known cure. Psoriasis is associated with an increased risk of psoriatic arthritis, lymphomas, cardiovascular disease, and Crohn’s disease. Psoriasis treatments today include steroid and vitamin D3 cream, ultraviolet light, and immune system suppressing medications such as methotrexate.
The T cells responsible for psoriasis are Th1 and Th l7 cells. IL-22, produced by Th17 cells, is crucial for the proliferation of keratinocytes. IL-22 with the help of IL-17 can induce the critical events of psoriasis. To maintain Th17 cells, IL-23 is required, and it is released from tumor necrosis factor-alpha (TNF-alpha) induced pathways. The pathophysiology of psoriasis involves RORC (retinoic acid receptor-related orphan nuclear receptor gamma) as a critical transcription factor for the development of Th17 cells. FDA has approved an antibody Secukinumab® targeting TNF-α for the treatment of psoriasis. Other FDA approved drugs are Tremfya® targeting IL23 for treatment of moderate to severe plaque psoriasis and Taltz® that blocks IL17 for treatment of plaque psoriasis.
Metadichol® a nano-formulation of long-chain lipid alcohols derived from food is a TNF-alpha inhibitor and also binds to Vitamin D receptor (VDR) that could have beneficial effects on Psoriasis. VDR modulates Th1-mediated inflammatory disease like psoriasis. We now present evidence that Metadichol is an inverse agonist of RORγt and AHR (Aryl Hydrocarbon Receptor) thus controlling Th17, IL17 and IL22. Being a TNF-alpha inhibitor, it can control IL23 thus blocking the significant pathways that exacerbate psoriasis. We present case studies of 7 patients afflicted with psoriasis and skin related conditions and how treatment with Metadichol resolved the underlying disease. Metadichol® has properties that allow its use as a safe nontoxic, toxic solution to combating the growing number of psoriasis cases.
This paper is published in the Journal of Clinical & Experimental Dermatological Research. Citation: Raghavan PR (2017) Metadichol, A Novel ROR Gamma Inverse Agonist and Its Applications in Psoriasis. J Clin Exp Dermatol Res 8: 433. doi:10.4172/2155-9554.1000433 This is an open access journal. Link Prr-Psoriasis-paper
Most diseases are connected through a network that is commonly called network pharmacology. The paper shows how Metadichol affects many different diseases through this network. It is definitely worth your time to look at the paper. Presented are seven case studies with psoriasis resolved. Picture here is whole body psoriasis that is resolved in twenty-four weeks. The participants used the spray orally and applied it directly to the areas of concern.
Other than Metadichol, I do believe that the over the counter ointment of vitamins A and D is the best. Metadichol appears to work along pathways for A and D. Typically, vitamins are currently recommended at levels that are to resolve basic body needs without looking at higher levels for improved health.